期刊
NATURE MEDICINE
卷 23, 期 1, 页码 28-38出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.4246
关键词
-
资金
- NIMH
- NIDA
- Autism Speaks
- NINDS
- NIH COBRE grant [1P20RR021938-01A2]
- Dana Foundation
- Hartwell Foundation
- International Mental Health Research Organization
- Klingenstein-Simons Foundations
- NIMH [R00 MH097822, R01 MH109685, P50 MH077083]
- HHMI
- NARSAD
Biomarkers have transformed modern medicine but remain largely elusive in psychiatry, partly because there is a weak correspondence between diagnostic labels and their neurobiological substrates. Like other neuropsychiatric disorders, depression is not a unitary disease, but rather a heterogeneous syndrome that encompasses varied, co-occurring symptoms and divergent responses to treatment. By using functional magnetic resonance imaging (fMRI) in a large multisite sample (n = 1,188), we show here that patients with depression can be subdivided into four neurophysiological subtypes ('biotypes') defined by distinct patterns of dysfunctional connectivity in limbic and frontostriatal networks. Clustering patients on this basis enabled the development of diagnostic classifiers (biomarkers) with high (82-93%) sensitivity and specificity for depression subtypes in multisite validation (n = 711) and out-of-sample replication (n = 477) data sets. These biotypes cannot be differentiated solely on the basis of clinical features, but they are associated with differing clinical-symptom profiles. They also predict responsiveness to transcranial magnetic stimulation therapy (n = 154). Our results define novel subtypes of depression that transcend current diagnostic boundaries and may be useful for identifying the individuals who are most likely to benefit from targeted neurostimulation therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据